Studies Show Eli Lilly Weight-Loss Drug Helps With Sleep Apnea
By Colin Kellaher
Eli Lilly said a pair of late-stage studies showed that its blockbuster weight-loss tirzepatide significantly reduced the severity of sleep apnea in overweight adults.
The company on Wednesday said tirzepatide, which met all primary and key secondary endpoints in the Phase 3 studies, reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea and obesity.
The Indianapolis drugmaker, which markets tirzepatide for chronic weight management as Zepbound in the U.S. and Mounjaro in some international markets, said it plans to submit the study data for global regulatory reviews.
Eli Lilly, which reported more than $5 billion in combined sales of Mounjaro and Zepbound last year, said that while there are pharmaceutical treatments for the excessive sleepiness associated with obstructive sleep apnea, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 17, 2024 06:57 ET (10:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now